What recent performance suggests about GeneDx Holdings

GeneDx Holdings (WGS) has drawn attention after a mixed run in its stock, with the price roughly flat over the past day, up about 16% over the past week, yet down over the past month and past 3 months.

Looking beyond the recent bounce, the stock has a 7-day share price return of 16.1%, but the 30-day and year to date share price returns are down 31.0% and 64.2% respectively, while the 3-year total shareholder return is very large.

If you are weighing GeneDx against other healthcare-focused AI opportunities, this is a good time to see what else is out there with the 34 healthcare AI stocks

So with the share price weak this year yet analysts' targets and intrinsic value estimates pointing higher, are you looking at a stock that is still undervalued, or has the market already priced in any potential future growth?

Most Popular Narrative: 68.2% Undervalued

Against a last close of $47.31, the most followed narrative puts GeneDx Holdings' fair value at $148.89, creating a wide gap investors will want to understand.

Rapid expansion into new and underpenetrated markets including general pediatrics (driven by American Academy of Pediatrics guidelines), NICU, and additional pediatric specialties positions GeneDx for substantial future volume and revenue growth as adoption of genomics as a frontline diagnostic tool accelerates. Scaling proprietary AI-powered genomic interpretation platforms and integrating newly acquired Fabric Genomics technology enhances efficiency and accuracy, which should both lower per-sample costs and support margin expansion as the business grows.

Curious what sits behind that fair value gap? The narrative leans on rapid revenue growth assumptions, improving margins and a rich profit outlook built on genomics adoption. See our AI narrative and valuation for GeneDx Holdings.

Result: Fair Value of $148.89 (UNDERVALUED)

However, this depends on reimbursement remaining supportive and competitors avoiding aggressive price cuts, while higher spending on expansion could weigh on cash flow if growth falls short of expectations.

Another view on GeneDx's valuation

While the narrative points to a large discount to fair value, the current P/S ratio of 3.2x tells a more cautious story. It sits well above the US Healthcare average of 1.2x and the peer average of 0.6x, even though it is below the fair ratio of 4x. This suggests the market could still move higher on this metric. Is the bigger risk that expectations are already rich?

Next Steps

With mixed signals on price and valuation, it helps to look past headlines and weigh both sides for yourself. To see how other investors balance the upside and downside in their own work, take a moment to review the 2 key rewards and 2 important warning signs

Looking for more investment ideas?

If GeneDx has caught your interest, do not stop here. Broader, well chosen ideas can help you build a stronger, more resilient portfolio over time.

• Spot potential bargains early by scanning screener containing 21 high quality undiscovered gems before they attract wider attention.
• Prioritize resilience and sleep easier at night by reviewing 68 resilient stocks with low risk scores that keep volatility in check.
• Strengthen your core holdings with the solid balance sheet and fundamentals stocks screener (46 results) that can better withstand tough conditions.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.